Multiple studies designed to evaluate chimeric antigen receptor (CAR) T-cell therapies in various hematologic malignancies appeared to show promise at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orland
This study indicated that caregivers saw improved quality of life, reduced caregiving burden, lower anxiety and depression symptoms, and improved self-efficacy and coping skills having received psychosocial intervention.
The treatment landscape for chronic lymphocytic leukemia has dramatically changed in the past decade.
Jennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications.
After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma.
Researchers report on the BRIGHT AML 1019 Phase III trial.
Researchers explore the predictive capability of EVI1 expression.
ONCOLOGY spoke to Andre Goy, MD, MS about advances on leukemia, lymphoma, and myeloma treatments.
ONCOLOGY discussed therapy options for adult acute lymphoblastic leukemia with Dr. Elias Jabbour, MD, Professor of Medicine in the Department of Leukemia at the MD Anderson Cancer Center in Houston, Texas.
Researchers looked at the effect of diagnostic wait time on survival outcomes for patients with diffuse large B-cell lymphoma.